Medication info

Keometformin Tablets 15/850 mg

Prescription medicationExpired
Ingredient · strength
Metformin Hydrochloride›Strength being verifiedPioglitazone Hydrochloride›Strength being verified
Manufacturer / importer
KMS Pharmaceutical Co., Ltd.
Appearance
White to pale gray rectangular film-coated tablets
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Expired

MFDS item code 201802861 · Approved 2018.07.10

This product's status changed to Expired on 2023.07.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. Patients should be carefully monitored for adverse reactions associated with fluid retention after starting this drug or increasing the dose. This drug should generally be administered in divided doses with meals; doing so may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
KMS Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control
  • Type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with Type 2 diabetes. It is particularly prescribed when adequate blood sugar control is difficult with monotherapy using either metformin or pioglitazone. It is also used as a substitute for combination therapy with metformin and pioglitazone. Management of Type 2 diabetes should occur in conjunction with nutritional counseling, weight loss, and physical activity; such lifestyle improvements are crucial for enhancing and maintaining the effects of the medication. Therefore, this medication is used to improve blood sugar control in conjunction with diet and exercise.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. Patients should be carefully monitored for adverse reactions associated with fluid retention after starting this drug or increasing the dose. This drug should generally be administered in divided doses with meals; doing so may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication helps control blood sugar levels. However, caution should be exercised for the rare side effect known as lactic acidosis while taking this medication. Lactic acidosis is a serious condition that occurs when there is an excessive accumulation of lactic acid in the body, and symptoms may include difficulty breathing, muscle pain, abdominal pain, and fatigue. If these symptoms occur, consult a physician immediately. Additionally, this medication should not be administered to patients with impaired kidney function or severe heart failure. Given that diminished kidney function can lead to drug accumulation in the body, this increases the risk of side effects. Regular kidney function testing is therefore essential. Patients with impaired liver function should also avoid using this medication, as compromised liver processing of drugs can aggravate side effects. Excessive alcohol intake may affect lactate metabolism when combined with this medication, making it risky; thus, avoidance of alcohol consumption is recommended. This medication may impose a burden on the heart, and patients with heart failure symptoms should be closely monitored. If symptoms of heart failure such as weight gain, swelling, or shortness of breath arise, medical personnel should be informed immediately. Patients with a history of bladder cancer or those with active bladder cancer should not use this medication and should report any new or worsening bladder-related symptoms to their doctor. Women who are pregnant, could become pregnant, or are breastfeeding should not take this medication. While using this medication, symptoms of hypoglycemia, in which blood sugar levels drop too low, may also occur, so caution is warranted when skipping meals or engaging in vigorous exercise. This is especially critical when taking other glucose-lowering agents concurrently. Elderly patients may be at risk for decreased kidney function, so careful dosage adjustments and regular monitoring of kidney function are advised during administration of this medication. If surgery or radiographic examinations using contrast agents are planned, the use of this medication should be temporarily halted, and it should only be resumed after confirming normal kidney function. While taking this medication, it is important to have regular blood sugar, hematological, and liver function tests to ensure there are no abnormalities.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • drowsiness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 31 more
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower extremity edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • liver failure
  • reduced vision
  • congestive heart failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • gastrointestinal air retention
  • increased serum creatinine
  • increased serum urea
  • fracture
  • increased ovulation
  • macular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius, and it is advisable to avoid excessively hot or cold places.

Appearance and packaging

Appearance

White to pale gray rectangular film-coated tablets

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.